- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04749628
Cannabidiol for Bilateral Total Knee Arthroplasty
April 8, 2024 updated by: Hospital for Special Surgery, New York
Effects of Cannabidiol (CBD) Oral Solution in Patients Undergoing Bilateral Total Knee Arthroplasty: a Randomized, Controlled, Parallel, Triple Blind, Pilot Study
In light of the opioid epidemic and evidence suggesting that cannabis may be opioid-sparing, we are in a unique position to conduct a novel, high-impact study that would set the stage for future RCTs examining the effects of a nonintoxicating and nonaddictive cannabinoid in an orthopedic patient population.
Epidiolex®, an oral cannabidiol (CBD) solution, is the first ever cannabis-derived medication to be approved by the Food & Drug Administration.
Our aim is to conduct a pilot study using a placebo oral solution, 400mg and 800mg Epidiolex® to gather data on its effects on patients undergoing bilateral total knee arthroplasty (BTKA).
We will be estimating whether Epidiolex® is associated with minimal opioid use and adequate analgesia.
We will also assess its tolerability, pharmacokinetics, and effects on inflammatory markers in the perioperative setting.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
36
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: William Chan, MEng
- Phone Number: 917-260-4788
- Email: chanw@hss.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- Hospital for Special Surgery
-
Contact:
- William Chan, MEng
- Phone Number: 917-260-4788
- Email: chanw@hss.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 to 75
- Scheduled for same-day bilateral total knee replacements with participating surgeons
- American Society of Anesthesiologists (ASA) Physical Status 1 or 2
Exclusion Criteria:
- ASA 3 and higher
- Weight < 40kg
- Planned use of general anesthesia
- Contraindication to major components of study protocol
- Cannabis or cannabinoid use within the past 3 months (recreational and/or medical)
- Use or ingestion of hemp seeds or hemp oil in any form within the past 30 days
- Chronic opioid use (>3 months)
- Coumadin use
- Current use of SSRI or SNRIs
- History of substance abuse or dependence
- Active or history of major psychiatric illness
- Severe cardiovascular disorder
- Severe hepatic or renal insufficiency (transaminase levels above ULN)
- History of epilepsy
- Diagnosis of rheumatic disease, autoimmune disease, or immunodeficiency (e.g. rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, etc.)
- Use of valproate or clobazam
- Known or suspected hypersensitivity, allergy, or contraindication to cannabinoids or any of the excipients in the study medications (i.e. sesame oil, sucralose, strawberry flavor)
- Active use of steroids - oral steroids upon admission
- Stress dose steroids
- Non-English speakers
- Planned discharge to home without caregiver(s)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Ora-sweet SF
|
Ora-sweet SF placebo
|
Experimental: 400mg cannabidiol
|
Epidiolex (cannabidiol) oral solution
Other Names:
|
Experimental: 800mg cannabidiol
|
Epidiolex (cannabidiol) oral solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Opioid Usage in First 72 hours Postoperatively
Time Frame: 0-72 hours postoperatively
|
Cumulative opioid usage over the first 72 hours after surgery.
Measured in morphine equivalents (ME), a scale that measure opioid usage among all opioid medications
|
0-72 hours postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of CBD
Time Frame: 0, 1, 2, 3, 4, 6 hours after medication administration
|
Levels of CBD in the blood.
This is measured using blood draws and lab analysis.
|
0, 1, 2, 3, 4, 6 hours after medication administration
|
Levels of Plasma Inflammatory Marker Interleukin-6
Time Frame: Preoperative, Postoperative day 1
|
Interleukin-6 (IL6) is an inflammatory marker found in plasma.
The levels of IL6 are measured using blood draws and lab analysis.
|
Preoperative, Postoperative day 1
|
NRS Pain at rest
Time Frame: Preoperatively; postoperatively in the PACU, morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Pain at rest measured using numerical rating scale(NRS) from 0-10, with 0 being no pain at all to 10 being the worst pain imaginable.
|
Preoperatively; postoperatively in the PACU, morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
NRS Pain with movement
Time Frame: Preoperatively; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Pain with movement using numerical rating scale(NRS) from 0-10, with 0 being no pain at all to 10 being the worst pain imaginable.
|
Preoperatively; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Brief Pain Inventory Short Form
Time Frame: Preoperatively; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Brief Pain inventory short form measures the severity of pain and its impact on function.
It measures pain from 0-10 0 being no pain whatsoever to 10 being the worst pain imaginable.
It measures impact on function from 0-10, 0 being no impact whatsoever to 10 being completely impactful.
|
Preoperatively; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Incidence of adverse events
Time Frame: Postoperatively in the PACU; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Adverse events, including allergic reactions, pyrexia (fever), somnolence (excessive sleepiness), GI problems (upset stomach, diarrhea), dry mouth, escalation of post-operative opioid requirement
|
Postoperatively in the PACU; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Opioid related Symptom Distress Scale (ORSDS)
Time Frame: Morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
ORSDS measures opioid related side effects.
There are 13 side effects with 3 subcategories (severity, frequency, bothersomeness) each with 5 different responses (scored 0-4).
|
Morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Anxiety levels
Time Frame: Preoperatively; Morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Hospital Anxiety and Depression Scale (HADS) asks 14 questions, 7 about anxiety and 7 about depression.
Responses are scored from 0-3.
Responses between the two categories are summed and scoring is as follows: 0-7 = normal, 8-10=borderlines abnormal, 11-21=abnormal
|
Preoperatively; Morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Cumulative inpatient analgesic use (non-opioid)
Time Frame: POD0 - POD3
|
Total non-opioid medication usage
|
POD0 - POD3
|
Opioid & non-opioid analgesic consumption
Time Frame: At hospital discharge to POD7 and at 3 months
|
Total opioid & non-opioid medication usage
|
At hospital discharge to POD7 and at 3 months
|
Hospital length of stay
Time Frame: End of surgery to hospital discharge
|
Length of stay measured in hours
|
End of surgery to hospital discharge
|
Blinding Assessment
Time Frame: POD4
|
Patients are asked which treatment they think they received.
The correctness of their guesses is then measured using the bang-blinding index to see if patients were able to accurately guess which treatment they received.
It is measured on a scale of -1 to 1. Scores closer to 0 indicate better blinding, or patients not being able to guess their treatment
|
POD4
|
Time to reach discharge physical therapy goals
Time Frame: At hospital discharge - up to 3 days after surgery
|
Physical therapy goals for total knee replacement include walking 100 feet, going up and down 4 stairs, and independent transfer (meaning they can move from a lying to standing position independently).
Patients need to complete these goals before being discharged
|
At hospital discharge - up to 3 days after surgery
|
Range of motion
Time Frame: preoperatively, 6 weeks postoperatively.
|
Range of motion, or extension and flexion of the knees, are measured preoperatively and at the patients' 6 week surgeon visit.
It is measured in degrees
|
preoperatively, 6 weeks postoperatively.
|
Sleep quality and duration
Time Frame: POD0 - POD3
|
Sleep quality assessed by actigraphy using ActiGraph wGT3X-BT activity monitor
|
POD0 - POD3
|
Sleep quality
Time Frame: preoperatively; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Sleep quality assessed by Leeds sleep evaluation questionnaire (LSEQ).
Responses to 10 questions will be measured on a slider scale ranging from 0-100.
|
preoperatively; morning of postoperative day (POD) 1,2,3,4,7 and at 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Alexandra Sideris, PhD, Hospital for Special Surgery, New York
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2022
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
February 5, 2021
First Submitted That Met QC Criteria
February 8, 2021
First Posted (Actual)
February 11, 2021
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-1688
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared.
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication
IPD Sharing Access Criteria
For researchers who provide a methodologically sound proposal and analyses to achieve aims in the approved proposal.
Proposals should be directed to siderisa@hss.edu.
To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Postoperative
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
Clinical Trials on Ora-sweet SF
-
Temple UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD); Monell...Active, not recruiting
-
Milton S. Hershey Medical CenterChildren's Miracle NetworkCompletedFontan CirculationUnited States
-
Bournemouth UniversityUniversity of BristolCompletedRepeated Sweet Food ConsumptionUnited Kingdom
-
Technische Universität DresdenCompleted
-
IWK Health CentreIWK FoundationCompleted
-
University of UtahCompletedSingle VentricleUnited States
-
Taipei Medical UniversityCompleted
-
Universitaire Ziekenhuizen KU LeuvenKU Leuven; Fund for Scientific Research, Flanders, BelgiumCompletedDisorder Related to Lung TransplantationBelgium
-
University of California, DavisUC Davis Foods for Health Institute; Mengniu DairyActive, not recruitingMicrobial Colonization | Infant DevelopmentUnited States
-
Taipei Medical UniversityCompleted